David Eidelberg
David Eidelberg | |
---|---|
Nationality | American |
Education | Columbia University, Harvard Medical School |
Occupation | Physician, Scientist |
Employer | The Feinstein Institute for Medical Research |
Known for | Medical Research |
Website |
David Eidelberg, MD, is a neuroscientist best known for applying functional imaging of the brain (MRI, PET scans) to diagnose neurological disease and chart its course. Eidelberg's studies were the first to identify specific changes in the patterns of brain-wide metabolic activity that could be linked to specific stages in the onset and development of Parkinson's disease and other movement disorders, such as dystonia, Tourette syndrome, and Huntington's disease.[1][2] The work has led to the development of novel image-based methods for assessing disease progression and responses to treatment, as well as for enhancing the accuracy of clinical diagnosis.
Early Life and Education
David Eidelberg earned his BA at Columbia University in 1977, and his MD from Harvard Medical School (HMS) in 1981.[3] After completing residency training in neurology at the Harvard-Longwood Area Training Program, he pursued postdoctoral training as a Moseley Traveling Fellow at the National Hospital, Queen Square, in London, and at Sloan-Kettering Institute in New York.
Academic Appointments
In 1988, David Eidelberg joined North Shore University Hospital in Manhasset, New York, where he established the Functional Brain Imaging Laboratory and the Movement Disorders Center. He is currently Director of the Feinstein Center for Neurosciences and Susan & Leonard Feinstein Professor of Neuroscience at The Feinstein Institute for Medical Research. He is also Director of the NIH Morris K. Udall Center of Excellence for Parkinson’s Disease Research, both at The Feinstein Institute for Medical Research in Manhasset, NY.[3] He is also an attending neurologist at North Shore University Hospital in Manhasset.
Principal Scientific Contributions
Eidelberg is internationally recognized for his pioneering work using functional imaging methods to characterize large-scale network abnormalities in brain disease. The characterization of distinct disease-specific metabolic networks relating to these disorders and the prospective quantification of pattern expression in individual cases have proved to be valuable for differential diagnosis and the objective assessment of disease progression and the effects of therapy. In particular, Eidelberg and his colleagues have used this approach to measure rates of network progression in preclinical carriers of the Huntington disease mutation, and in individuals with prodromal Parkinson's disease.[4] Additionally, his team was the first to demonstrate a consistent relationship between treatment-mediated network modulation in individual patients (measured using functional brain imaging) and independent descriptors of therapeutic outcome (measured using standardized clinical ratings).[5] This work set the stage for the recent introduction of functional brain networks as imaging biomarkers with which to assess novel therapies, such as gene therapy interventions for Parkinson’s disease. Eidelberg's network method has also proved useful in clarifying mechanisms of clinical penetrance in dominantly inherited neurological disorders such as primary torsion dystonia and Huntington’s disease.
Awards and Honors
- American Academy of Neurology Movement Disorders Research Award, 2010[6]
- American Parkinson Disease Association Fred Springer Award, 2005
- Scientific Advisory Board Member: Michael J. Fox Foundation, 2004–present[7]
- Scientific Advisory Board Member: Bachmann-Strauss Dystonia and Parkinson Foundation, 2009–present[8]
- Scientific Director of The Thomas Hartman Foundation for Parkinson’s Research, 2007–present[9]
- Editorial Board Member: Journal of Nuclear Medicine (1999–present),[10] Current Opinion in Neurology (2001–present),[11] and Annals of Neurology (2006–present)[12]
- Associate Editor: Journal of Neuroscience (2010–present)[13]
Selected Publications (2006–2014)
- Book: Imaging in Parkinson’s disease. Eidelberg D, editor. New York: Oxford University Press; 2011
- Ulug, AM; Vo, A; Argyelan, M; Tanabe, L; Schiffer, WK; Dewey, S; Dauer, WT; Eidelberg, D (2011). "Selective motor system abnormalities in DYT1 mutant TorsinA knock-in mice". Proc Natl Acad Sci USA. 108 (16): 6638–6643.
- Carbon, M; Argyelan, M; Ghilardi, MF; Mattis, P; Dhawan, V; Bressman, S; Eidelberg, D (2011). "Impaired sequence learning in dystonia mutation carriers: a genotypic effect". Brain. 134 (5): 1416–27. doi:10.1093/brain/awr060.
- Pourfar, M; Feigin, A; Tang, CC; Carbon-Correll, M; Bussa, M; Budman, C; Dhawan, V; Eidelberg, D (2011). "Abnormal metabolic brain networks in Tourette syndrome". Neurology. 76 (11): 944–952. doi:10.1212/wnl.0b013e3182104106.
- Spetsieris, PG; Eidelberg, D (2011). "Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues". NeuroImage. 54: 2899–2914. doi:10.1016/j.neuroimage.2010.10.025.
- Mure, H; Hirano, S; Tang, CC; Isaias, IU; Antonini, A; Ma, Y; Dhawan, V; Eidelberg, D (2011). "Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects". NeuroImage. 54 (2): 1244–53. doi:10.1016/j.neuroimage.2010.09.028. PMC 2997135. PMID 20851193.
- Ma, Y; Huang, C; Dyke, JP; Pan, H; Feigin, A; Eidelberg, D (2010). "Parkinson's disease spatial covariance pattern: Non-invasive quantification with perfusion MRI". J Cereb Blood Flow Metab. 30 (3): 505–9. doi:10.1038/jcbfm.2009.256.
- Carbon, M; Argyelan, M; Habeck, C; Ghilardi, MF; Fitzpatrick, T; Dhawan, V; Pourfar, M; Bressman, SB; Eidelberg, D (2010). "Increased sensorimotor network activity in DYT1 dystonia: A functional imaging study". Brain. 133 (3): 690–700. doi:10.1093/brain/awq017. PMC 2842516. PMID 20207699.
- Tang, C; Poston, K; Eckert, T; Feigin, A; Frucht, S; Gudesblatt, M; Dhawan, V; Lesser, M; Vonsattel, J-P; Fahn, S; Eidelberg, D (2010). "Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis". Lancet Neurol. 9 (2): 149–58. doi:10.1016/s1474-4422(10)70002-8.
- Tang, C; Poston, K; Dhawan, V; Eidelberg, D (2010). "Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease". J Neurosci. 30 (3): 1049–56. doi:10.1523/jneurosci.4188-09.2010.
- Pourfar, M; Tang, C; Lin, T; Dhawan, V; Kaplitt, M; Eidelberg, D (2009). "Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET". J Neurosurg. 110 (6): 1278–82. doi:10.3171/2008.12.jns08991.
- Argyelan, M; Carbon, M; Niethammer, M; Ulug, AM; Henning, UV; Bressman, SB; Dhawan, V; Eidelberg, D (2009). "Cerebello-thalamo-cortical connectivity regulates penetrance in dystonia". J Neurosci. 29 (31): 9740–7. doi:10.1523/jneurosci.2300-09.2009.
- Eidelberg, D (2009). "Metabolic brain networks in neurodegenerative disorders: a functional imaging approach". Trends Neurosci. 32 (10): 548–57. doi:10.1016/j.tins.2009.06.003.
- Carbon, M; Niethammer, M; Peng, S; Raymond, D; Dhawan, V; Chaly, T; Ma, Y; Bressman, S; Eidelberg, D (2009). "Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia". Neurology. 72 (24): 2097–103. doi:10.1212/wnl.0b013e3181aa538f.
- Argyelan, M; Carbon, M; Ghilardi, MF; Feigin, A; Mattis, P; Dhawan, V; Eidelberg, D (2008). "Dopaminergic suppression of brain deactivation responses during sequence learning". J Neurosci. 28 (42): 10687–95. doi:10.1523/jneurosci.2933-08.2008.
- Lin, T; Carbon, M; Tang, C; Mogilner, A; Sterio, D; Beric, A; Dhawan, V; Eidelberg, D (2008). "Metabolic correlates of subthalamic nucleus activity in Parkinson's disease". Brain. 131 (5): 1373–80. doi:10.1093/brain/awn031.
- Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. "Metabolic abnormalities associated with mild cognitive impairment in Parkinson’s disease" Neurology 2008; 70(16 Pt 2) 1470-7
- Hirano, S; Asanuma, K; Ma, Y; Tang, C; Feigin, A; Dhawan, V; Carbon, M; Eidelberg, D (2008). "Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease". J Neurosci. 28 (16): 4201–9. doi:10.1523/jneurosci.0582-08.2008.
- Feigin, A; Kaplitt, MG; Tang, C; Lin, T; Dhawan, V; During, MJ; Eidelberg, D (2007). "Modulation of metabolic brain networks following subthalamic gene therapy for Parkinson's disease". Proc Natl Acad Sci USA. 104 (49): 19559–64.
- Carbon, M; Ghilardi, M-F; Argyelan, M; Dhawan, V; Bressman, S; Eidelberg, D (2008). "Increased cerebellar activation during sequence learning in DYT1 carriers: An equiperformance study". Brain. 131 (1): 146–54. doi:10.1093/brain/awm243.
- Huang, C; Tang, C; Feigin, A; Lesser, M; Ma, Y; Pourfar, M; Dhawan, V; Eidelberg, D (2007). "Changes in network activity with the progression of Parkinson's disease". Brain. 130 (7): 1834–46. doi:10.1093/brain/awm086.
- Kaplitt, M; Feigin, A; Tang, C; Fitzsimons, H; Mattis, P; Lawlor, P; Bland, R; Young, D; Strybing, K; Eidelberg, D; During, M (2007). "Safety and tolerability of AAV-GAD gene therapy for Parkinson's disease: An open label, phase I trial". Lancet. 369 (9579): 2097–2105. doi:10.1016/s0140-6736(07)60982-9.
- Ma, Y; Tang, C; Spetsieris, P; Dhawan, V; Eidelberg, D (2007). "Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility". J Cereb Blood Flow Metab. 27 (3): 597–605. doi:10.1038/sj.jcbfm.9600358.
- Feigin, A; Tang, C; Ma, Y; Mattis, P; Zgaljardic, D; Guttman, M; Paulsen, JS; Dhawan, V; Eidelberg, D (2007). "Thalamic metabolism and symptom onset in preclinical Huntington's disease". Brain. 130 (11): 2858–67. doi:10.1093/brain/awm217.
- Huang, C; Mattis, P; Tang, C; Perrine, K; Carbon, M; Eidelberg, D (2007). "Metabolic brain networks associated with cognitive function in Parkinson's disease". NeuroImage. 34 (2): 714–23. doi:10.1016/j.neuroimage.2006.09.003.
- Asanuma, K; Tang, C; Ma, Y; Dhawan, V; Mattis, P; Edwards, C; Kaplitt, MG; Feigin, A; Eidelberg, D (2006). "Network modulation in the treatment of Parkinson's disease". Brain. 129 (10): 2667–78. doi:10.1093/brain/awl162.
References
- ↑ "Increased sensorimotor network activity in DYT1 dystonia: A functional imaging study". Brain. 133 (Pt 3): 690–700. 2010. doi:10.1093/brain/awq017. PMC 2842516. PMID 20207699.
- ↑ "Abnormal metabolic brain networks in Tourette syndrome". Neurology. 76 (11): 944–952. 2011. doi:10.1212/WNL.0b013e3182104106. PMC 3271575. PMID 21307354.
- 1 2 "Centers of Excellence". The Feinstein Institute for Medical Research. Retrieved 5 February 2014.
- ↑ "Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects". NeuroImage. 54 (2): 1244–53. 2011. doi:10.1016/j.neuroimage.2010.09.028. PMC 2997135. PMID 20851193.
- ↑ "Network modulation in the treatment of Parkinson's disease". Brain. 129 (Pt 10): 2667–78. 2006. doi:10.1093/brain/awl162.
- ↑ "Past Award Winners". American Academy of Neurology. Retrieved 5 February 2014.
- ↑ "Scientific and Special Advisors". Michael J. Fox Foundation. Retrieved 5 February 2014.
- ↑ "Scientific Advisory Board". Bachmann-Strauss Dystonia and Parkinson Foundation. Retrieved 5 February 2014.
- ↑ "Striking at the Causes of Parkinson's" (PDF). The Thomas Hartman Foundation for Parkinson's Research, Inc. Retrieved 5 February 2014.
- ↑ "Editorial Board". Journal of Nuclear Medicine. Retrieved 5 February 2014.
- ↑ "Editorial Board". Current Opinion in Neurology. Retrieved 5 February 2014.
- ↑ "Editorial Board". Annals of Neurology. Retrieved 5 February 2014.
- ↑ "About The Journal of Neuroscience". The Journal of Neuroscience. Retrieved 5 February 2014.